# OnCo record ab-1015 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ab-1015/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ab-1015" ;
  schema:name "AB-1015"@en ;
  schema:description "AB-1015 is an experimental autologous Integrated Circuit T cell therapy from Arsenal Biosciences, in phase 1 trials for platinum-resistant high-grade serous ovarian, fallopian tube and primary peritoneal cancer; its current status is not stated."@en ;
  schema:url <https://onco.cc/drugs/ab-1015/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://arsenalbio.com/2024/04/30/arsenal-biosciences-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-ab-2100-in-development-as-a-treatment-for-clear-cell-renal-cell-carcinoma/>, <https://clinicaltrials.gov/api/v2/studies/NCT05617755>, <https://clinicaltrials.gov/search?intr=AB-1015> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Autologous Integrated Circuit T (ICT) cell therapy" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:companies <https://onco.cc/companies/arsenal-bio/> ;
  onco:trials <https://onco.cc/trials/nct05617755/> .